Objective: To evaluate the surgical resection rates and clinical outcomes in patients with locally advanced pancreatic cancer (LAPC) after neoadjuvant treatment based on FOLFIRINOX regimen (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin). Methods: The clinical studies regarding LAPC undergoing surgical resection after FOLFIRINOX-based treatment were collected by searching several national and international online databases. The retrieval time was from inception of the database to January 2016. Meta-analysis was performed on the enrolled studies by using STATA 12.0 software. Results: Fourteen studies involving 714 LAPC patients were included. Results of Meta-analysis showed that in LAPC patients receiving FOLFIRINOX-based treatment prior to surgical resection, the resection rate was 59% (95% CI=0.46–0.72, P=0.0001) in which the R0 rate was 70.0% (95% CI=0.51–0.88, P=0.001); the median overall survival was 20.63 months (95% CI=16.54–24.73, P=0.001) and median progression-free survival was 13.54 months (95% CI=10.54–16.54, P=0.0001); the incidence of adverse reactions was 8% (95% CI=0.05–0.11, P=0.0001). Conclusion: For LAPC, FOLFIRINOX-based neoadjuvant treatment can increase the resection rates and opportunity of R0 resection,and improve the overall survival of the patients, with low incidence of adverse reactions. So it is recommended as a preferred regimen.